Show simple item record

dc.contributor.authorRojas, Armando
dc.contributor.authorFuentes, Eduardo
dc.contributor.authorPalomo, Iván
dc.description.abstractWhile platelets are well known to play a central role in hemostasis and thrombosis, there is emerging experimental evidence to suggest that they also mediate tumor cell growth, angiogenesis and metastasis. The receptor for advanced glycation end products (RAGE) has been extensively reported in many tumor types and initiates a downstream proinflammatory signaling cascade. RAGE ligands are expressed and secreted by tumor cells and are associated with poorer outcomes in a wide variety of tumors. In addition RAGE has been identified on human platelets and RAGE ligands may contribute to platelet activation. Therefore in the tumor microenvironment, upon activation, activated platelets interact with tumor cells through paracrine signaling and direct contact, thereby promoting tumor cell growth and thrombosis. Therefore, according to what is mentioned in this article, RAGE expression and its ligands could be a useful serological biomarker for diagnosis and treatment of cancer, as well as molecular target for novel forms of therapies.es_CL
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
dc.sourceBlood Reviews, 30(3), 213-221es_CL
dc.subjectTumor celles_CL
dc.subjectTumor microenvironmentes_CL
dc.titleCross-talk between platelet and tumor microenvironment: Role of multiligand/RAGE axis in platelet activationes_CL
dc.ucm.facultadFacultad de Medicinaes_CL

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile